Across TCGA pan-cancer cohorts, TAS2R13 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TAS2R13 data layer compared with 16 for mass-spec protein.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TAS2R13 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TAS2R13 expression acts as an unfavorable survival marker.
LIHC, ESCA, and GBM are the cancer types where TAS2R13 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.